New hope for stubborn gut cancers? early trial launches
NCT ID NCT07216560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental drug called 7MW4911 in 200 people with advanced colorectal or other gastrointestinal cancers that have progressed after standard treatments. The main goals are to find a safe dose and to see if the drug can shrink tumors. It is the first time this drug is being studied in humans in the US.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
7MW4911 (an experimental drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced gastrointestinal cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early first-in-human study, so the drug may not work or could cause unexpected side effects. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hematology Oncology Associates of the Treasure Coast
RECRUITINGPort Saint Lucie, Florida, 34952, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START
RECRUITINGLong Island City, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Moutain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••